Literature DB >> 10462606

Simplified Reverse Dot Blot Analyses for Detecting of ras Oncogene Mutations.

.   

Abstract

Background: Mutations in members of the ras gene family (H-ras, K-ras, and N-ras) have been identified in various human malignancies. A variety of techniques have been used to test for ras mutations. Methods and
Results: A simplified reverse dot blot (RDB) assay was used in this study. Polymerase chain reaction products were hybridized to nitrocellulose membrane-fixed synthetic probes (20 nucleotides long) specific for codons 12, 13, and 61 of H-, K-, and N-ras mutations and their wild-type sequences. No special treatment or modification of the probes was necessary to obtain adequate results in overnight film exposure when the polymerase chain reaction was carried out using (32)P-end labeled primers. It was demonstrated that this simplified RDB assay can also be used with fluorescein-11-dUTP and a chemiluminescence detection system. The RDB assay is more reliable than the single-strand conformation polymorphism (SSCP) assay. By comparison, the SSCP assay is significantly less sensitive and less specific. It was confirmed with sequencing that 11 (12%) of 93 SSCP assays were false positive and 2 (2%) were false negative, whereas no false positive or false negative RDB assay was detected. The RDB assay also provides more additional detailed information about the specific point mutation and amino acid change, which may have clinical implications in some tumors. Conclusions: The RDB assay is very sensitive and able to detect mutations when the mutant allele is in 1% of the cells and can be used to detect minimal residual disease, particularly in some cases of leukemia and myelodysplasia.

Entities:  

Year:  1997        PMID: 10462606     DOI: 10.1054/MODI00200169

Source DB:  PubMed          Journal:  Mol Diagn        ISSN: 1084-8592


  3 in total

1.  Sensitive sequencing method for KRAS mutation detection by Pyrosequencing.

Authors:  Shuji Ogino; Takako Kawasaki; Mohan Brahmandam; Liying Yan; Mami Cantor; Chungdak Namgyal; Mari Mino-Kenudson; Gregory Y Lauwers; Massimo Loda; Charles S Fuchs
Journal:  J Mol Diagn       Date:  2005-08       Impact factor: 5.568

Review 2.  Clinical relevance of KRAS in human cancers.

Authors:  Sylwia Jancík; Jirí Drábek; Danuta Radzioch; Marián Hajdúch
Journal:  J Biomed Biotechnol       Date:  2010-06-07

3.  High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.

Authors:  Michael Krypuy; Genni M Newnham; David M Thomas; Matthew Conron; Alexander Dobrovic
Journal:  BMC Cancer       Date:  2006-12-21       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.